BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Genetown

  Spyre Therapeutics Announces $180 Million Private Placement

  Spyre Therapeutics, Inc. announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses.

  December 7, 2023

   · 

  6 min read
• Policy

  EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic

  EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic.

  December 7, 2023

   · 

  3 min read
• Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals

  Full-Life Technologies, a fully integrated global radiotherapeutics company, announced the construction of its new Good Manufacturing Practices compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.

  December 7, 2023

   · 

  2 min read
• Business

  Cassava Sciences Appoints Three New Members to its Board of Directors

  Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the appointment of three new members to its Board of Directors, effective immediately.

  December 7, 2023

   · 

  2 min read
• Biotech Bay

  Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

  Exelixis, Inc. announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST.

  December 7, 2023

   · 

  1 min read
• Business

  Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023

  Avid Bioservices, Inc. (NASDAQ:CDMO) today announced financial results for the second quarter and six months ended October 31, 2023.

  December 7, 2023

   · 

  18 min read
• ICON Secures Upgraded Credit Rating from Moody’s Investors Service

  ICON plc, a world-leading healthcare intelligence and clinical research organization, announced that Moody’s Investors Service upgraded all of ICON plc’s instrument ratings to Baa3 with a stable outlook.

  December 7, 2023

   · 

  3 min read
• Enhanced Protection for Manufacturing Highly Potent Pharmaceuticals Introduced at New Jersey Facility

  Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry

  December 7, 2023

   · 

  1 min read
• Genetown

  Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

  Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.

  December 7, 2023

   · 

  7 min read
• Drug Development

  Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

  Hansa Biopharma, “Hansa”, announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.

  December 7, 2023

   · 

  5 min read